OLUWATOSIN FALOMO: Open Payments
NPI 1649041609 · BROOKSVILLE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$920 in 9 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $720 · 2025 $920
Food & beverage: $920
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 3 | $280 |
| Lundbeck LLC | 1 | $121 |
| Neurocrine BioSciences, Inc. | 1 | $121 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $111 |
| Merck Sharp & Dohme LLC | 1 | $110 |
| ABBVIE INC. | 1 | $88 |
| ARGENX US, INC. | 1 | $88 |
Products named: OTEZLA, VYEPTI, INGREZZA, CAPLYTA, CAPVAXIVE, EVENITY, QULIPTA, VYVGART.
Industry payments across FL — which companies pay providers there.
